What Do We Really Know About the Effect of Prolonged Heart Rhythm Monitoring After Stroke?

Håkon Ihle-Hansen*, Guri Hagberg, Hege Ihle-Hansen, Else Chartlotte Sandset, Jason G Andrade, John Mandrola, Søren Zöga Diederichsen

*Corresponding author af dette arbejde

Abstract

The bulk of the current knowledge on atrial fibrillation (AF)-associated stroke risk and benefit of oral anticoagulation derives from studies on patients with clinically diagnosed AF. Subclinical AF (SCAF), defined as AF discovered during the interrogation of prolonged heart monitoring, is often asymptomatic and short-lasting, is associated with increased stroke risk compared with sinus rhythm, and may progress to clinical AF. Despite the extensive screening for and treatment of SCAF, especially in secondary stroke prevention, the net benefit of this practice is not established. Recent studies of SCAF have provided new insights: (1) SCAF is extremely common and may sometimes indicate physiological findings, (2) the stroke risk associated with SCAF is lower than that of clinically detected AF, and (3) any benefit on stroke risk may be countered by increased bleeding risk (no net benefit). How should we interpret the latest knowledge in the setting of poststroke AF screening and prevention?

OriginalsprogEngelsk
TidsskriftStroke
Vol/bind55
Udgave nummer4
Sider (fra-til)1136-1140
Antal sider5
ISSN0039-2499
DOI
StatusUdgivet - apr. 2024

Fingeraftryk

Dyk ned i forskningsemnerne om 'What Do We Really Know About the Effect of Prolonged Heart Rhythm Monitoring After Stroke?'. Sammen danner de et unikt fingeraftryk.

Citationsformater